Published in Clin Infect Dis on June 01, 2008
Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother (2009) 2.83
Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev (2015) 1.94
Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J Clin Microbiol (2009) 1.64
Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J Infect Dis (2011) 1.59
Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother (2009) 1.47
Protein binding: do we ever learn? Antimicrob Agents Chemother (2011) 1.46
Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother (2008) 1.43
Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother (2009) 1.35
CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother (2012) 1.17
Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob Agents Chemother (2009) 1.16
Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method. Antimicrob Agents Chemother (2014) 1.14
Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance? Semin Immunopathol (2011) 1.06
Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother (2009) 1.02
Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers. Antimicrob Agents Chemother (2010) 1.02
In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob Agents Chemother (2010) 1.02
Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay. Antimicrob Agents Chemother (2010) 1.01
Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother (2011) 1.00
Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function. Antimicrob Agents Chemother (2012) 0.98
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis (2014) 0.96
Postantibiotic effects of telavancin against 16 gram-positive organisms. Antimicrob Agents Chemother (2009) 0.96
Telavancin. Nat Rev Drug Discov (2009) 0.94
Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA. Future Microbiol (2011) 0.92
In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Chemother (2012) 0.91
Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One (2012) 0.91
In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob Agents Chemother (2009) 0.90
Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob Agents Chemother (2012) 0.90
Telavancin (vibativ), a new option for the treatment of gram-positive infections. P T (2011) 0.89
Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus. Antimicrob Agents Chemother (2009) 0.88
Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother (2013) 0.84
Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections. Infect Drug Resist (2011) 0.83
Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits. Antimicrob Agents Chemother (2009) 0.82
Clinical MRSA isolates from skin and soft tissue infections show increased in vitro production of phenol soluble modulins. J Infect (2015) 0.82
Telavancin: A novel lipoglycopeptide antibiotic. J Pharmacol Pharmacother (2011) 0.81
Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol (2014) 0.81
Increased in vitro phenol-soluble modulin production is associated with soft tissue infection source in clinical isolates of methicillin-susceptible Staphylococcus aureus. J Infect (2016) 0.80
Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clin Proc (2012) 0.79
Role of telavancin in treatment of skin and skin structure infections. Clin Cosmet Investig Dermatol (2010) 0.78
Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). Clin Med Rev Ther (2011) 0.78
New developments in the management of severe skin and deep skin structure infections - focus on tedizolid. Ther Clin Risk Manag (2015) 0.77
Update on the emerging role of telavancin in hospital-acquired infections. Ther Clin Risk Manag (2015) 0.77
Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies. Infect Dis Ther (2017) 0.77
Kidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother (2015) 0.75
Post-reconstitution Stability of Telavancin with Commonly Used Diluents and Intravenous Infusion Solutions. Curr Ther Res Clin Exp (2015) 0.75
New drugs approved in 2009. Proc (Bayl Univ Med Cent) (2010) 0.75
Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis. Ther Clin Risk Manag (2016) 0.75
Oritavancin for acute bacterial skin and skin structure infections. Expert Opin Pharmacother (2015) 0.75
Randomized, controlled, multicentre clinical trial of the antipyretic effect of intravenous paracetamol in patients admitted to hospital with infection. Br J Clin Pharmacol (2016) 0.75
Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus. Infect Dis Ther (2016) 0.75
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance. Antimicrob Agents Chemother (2015) 0.75
Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis. Clin Drug Investig (2016) 0.75
Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer? Front Pharmacol (2016) 0.75
Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer. Antimicrob Agents Chemother (2015) 0.75
In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates. Antimicrob Agents Chemother (2009) 0.75
Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus. Infect Drug Resist (2009) 0.75
Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. BMC Infect Dis (2017) 0.75
Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus. Antimicrob Agents Chemother (2013) 0.75
Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia. Adv Ther (2016) 0.75
Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus. Antimicrob Agents Chemother (2017) 0.75
Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Ther Adv Infect Dis (2017) 0.75
Antimicrobial Activity and Resistance: Influencing Factors. Front Pharmacol (2017) 0.75
Efficacy of Ceftaroline in a Rat Model of Endocarditis Against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High Inoculum Effect. Antimicrob Agents Chemother (2017) 0.75
Once-Daily Treatments for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Are They Good Enough? Curr Infect Dis Rep (2017) 0.75
Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med (2011) 10.29
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med (2006) 8.20
Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med (2009) 7.82
Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA (2005) 7.41
Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med (2002) 7.35
Patient experiences and attitudes about access to a patient electronic health care record and linked web messaging. J Am Med Inform Assoc (2004) 5.78
Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med (2015) 4.80
Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2008) 4.48
Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis (2003) 4.06
Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med (2014) 3.86
In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med (2013) 3.72
Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis (2006) 3.70
Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis (2004) 3.35
Genetic and phenotypic variation of West Nile virus in New York, 2000-2003. Am J Trop Med Hyg (2004) 3.34
Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med (2003) 3.31
Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med (2006) 3.25
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis (2011) 3.20
Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA (2007) 3.03
Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. JAMA (2012) 3.01
Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother (2007) 2.89
Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J (2004) 2.85
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation (2015) 2.84
Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis (2004) 2.83
Tissue-dependent paired expression of miRNAs. Nucleic Acids Res (2007) 2.82
A simple epidural simulator: a blinded study assessing the 'feel' of loss of resistance in four fruits. Eur J Anaesthesiol (2013) 2.72
Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med (2002) 2.68
Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia. Clin Infect Dis (2011) 2.62
Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ (2011) 2.61
Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis (2013) 2.44
Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis (2005) 2.36
Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis (2006) 2.35
Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother (2005) 2.34
Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA (2013) 2.33
The surgeon and AIDS: twenty years later. Arch Surg (2005) 2.32
Gastrointestinal hemorrhage after laparoscopic gastric bypass. Obes Surg (2004) 2.27
Clinical predictors of major infections after cardiac surgery. Circulation (2005) 2.27
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis (2005) 2.26
Early predictors of in-hospital death in infective endocarditis. Circulation (2004) 2.26
The nonoperative management of periprosthetic fractures associated with the Birmingham hip resurfacing procedure. J Arthroplasty (2005) 2.23
An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23
Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J (2004) 2.19
Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibiotics. J Pediatr Gastroenterol Nutr (2010) 2.13
The relationship between hospital volume and outcome in bariatric surgery at academic medical centers. Ann Surg (2004) 2.07
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther (2007) 2.07
Outbreak of leptospirosis among triathlon participants and community residents in Springfield, Illinois, 1998. Clin Infect Dis (2002) 2.02
Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation (2010) 2.01
Complications after laparoscopic gastric bypass: a review of 3464 cases. Arch Surg (2003) 2.01
Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J Infect Dis (2007) 2.00
Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. JAMA (2002) 1.99
Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? Pediatrics (2006) 1.98
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis (2005) 1.95
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis (2010) 1.92
Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis (2005) 1.92
Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol (2007) 1.91
Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. Am Heart J (2004) 1.90
Fetal health surveillance: antepartum and intrapartum consensus guideline. J Obstet Gynaecol Can (2007) 1.90
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother (2006) 1.84
Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis (2011) 1.83
Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2008) 1.82
Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis (2009) 1.80
Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis (2004) 1.80
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis (2010) 1.78
Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis (2007) 1.78
Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol (2005) 1.77
Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med (2009) 1.76
Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis (2004) 1.73
Laparoscopic surgery is associated with a lower incidence of venous thromboembolism compared with open surgery. Ann Surg (2007) 1.73
Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography. Eur J Echocardiogr (2011) 1.72
Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremia. Crit Care Med (2008) 1.69
Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol (2005) 1.69
Colour of bile vomiting in intestinal obstruction in the newborn: questionnaire study. BMJ (2006) 1.68
Vascularity of the femoral head after Birmingham hip resurfacing. A technetium Tc 99m bone scan/single photon emission computed tomography study. J Arthroplasty (2006) 1.67